高级检索
当前位置: 首页 > 详情页

Cancer Stem Cell Marker Endoglin (CD105) Induces Epithelial Mesenchymal Transition (EMT) but Not Metastasis in Clear Cell Renal Cell Carcinoma

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

单位: [1]HUST,Tongji Med Coll,Tongji Hosp,Dept Urol,Wuhan 430030,Hubei,Peoples R China [2]HUST,Tongji Med Coll,Tongji Hosp,Inst Urol,Wuhan 430030,Hubei,Peoples R China [3]HUST,Tongji Med Coll,Tongji Hosp,Dept Pediat Surg,Wuhan 430030,Hubei,Peoples R China [4]Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA [5]Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA
出处:
ISSN:

摘要:
Clear cell renal cell carcinoma (ccRCC) is the most common histological subtype of kidney cancer. We previously reported that CD105(+) subpopulation in human ccRCC tumors possesses tumor cell self-renewal and chemoresistance capability. In this study, we showed that CD105(+) ACHN tumor cells exhibit epithelial mesenchymal transition (EMT) phenotype with high expression of mesenchymal marker N-cadherin and low expression of epithelial marker E-cadherin. They are more motile and invasive compared to the unselected parental ACHN tumor cells. The knockdown of CD105 by RNA interference led to the downregulation of N-cadherin and the upregulation of E-cadherin and reduced motility and invasiveness of CD105(+) cells. Overexpression of stem cell factor MYC in CD105 knocked down cells increased mesenchymal markers and cell motility. However, the CD105(+) population of tumor cells does not exhibit an increase metastatic potential in vivo. Findings from this study support that CD105 plays a functional role in maintaining cancer stem cell and EMT phenotype, with MYC as a common mediator for both of these traits. Our work suggests that the ability to metastasize does not coincide with the cancer stem cell or EMT function of CD105.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2018]版:
大类 | 2 区 医学
小类 | 3 区 细胞与组织工程
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 细胞与组织工程
JCR分区:
出版当年[2017]版:
Q2 CELL & TISSUE ENGINEERING
最新[2023]版:
Q2 CELL & TISSUE ENGINEERING

影响因子: 最新[2023版] 最新五年平均 出版当年[2017版] 出版当年五年平均 出版前一年[2016版] 出版后一年[2018版]

第一作者:
第一作者单位: [1]HUST,Tongji Med Coll,Tongji Hosp,Dept Urol,Wuhan 430030,Hubei,Peoples R China [2]HUST,Tongji Med Coll,Tongji Hosp,Inst Urol,Wuhan 430030,Hubei,Peoples R China [3]HUST,Tongji Med Coll,Tongji Hosp,Dept Pediat Surg,Wuhan 430030,Hubei,Peoples R China [4]Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA
通讯作者:
通讯机构: [1]HUST,Tongji Med Coll,Tongji Hosp,Dept Urol,Wuhan 430030,Hubei,Peoples R China [2]HUST,Tongji Med Coll,Tongji Hosp,Inst Urol,Wuhan 430030,Hubei,Peoples R China [4]Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA [5]Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:426 今日访问量:0 总访问量:408 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)